Lenders tipped a company which owns the vessel into receivership last month – before handing it back. He is attempting to refinance his sprawling hotel empire.
After another knockback from the US regulator, its sceptics say it’s business as usual. And Mesoblast chief executive Silviu Itescu remains as optimistic as ever.
The biotech, which is developing treatments for cardiovascular disease and back pain, is no stranger to the capital markets. It went into a trading halt on Thursday.